EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial

Qian Ren iD, Ling Li, Xiuhai Su, Xiaolin Hu, Guijun Qin iD, Jie Han, Yu Liu, Junmin Wang, Linong Ji iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15915 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Qian Ren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Drug Therapy, Combination, Glycated Hemoglobin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Haisco Pharmaceutical Group Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We evaluated the efficacy and safety of cofrogliptin, a novel dipeptidyl peptidase‐4 inhibitor taken once every 2 weeks (Q2W), compared with linagliptin (taken daily) in patients with type 2 diabetes inadequately controlled on metformin in China. Materials and Methods In this phase 3 randomized, double‐blind, active‐controlled, multicentre study, patients were randomly assigned 1:1:1 to receive cofrogliptin 10 mg Q2W, cofrogliptin 25 mg Q2W, or linagliptin 5 mg daily, all as an add‐on treatment to metformin, for 24 weeks. Eligible patients could enter an open‐label extension period and receive cofrogliptin 25 mg Q2W for an additional 28 weeks. The primary endpoint was change in glycated haemoglobin from baseline to 24 weeks, with a non‐inferiority margin of 0.4% for cofrogliptin versus linagliptin treatment.

Results

Overall, 465 patients entered the 24‐week treatment period (median age: 57.0 years). The least‐squares mean (standard error) change in glycated haemoglobin from baseline to week 24 was −0.96 (0.063), −0.99 (0.064) and −1.07 (0.065) for the cofrogliptin 10 mg, cofrogliptin 25 mg and linagliptin 5 mg groups, respectively. The between‐group difference met the predefined margin for non‐inferiority of cofrogliptin (10 and 25 mg) versus linagliptin treatment. The incidence of common adverse events (≥5% patients) during the 24‐week treatment period was similar between treatment groups. There were no serious hypoglycaemic events.

Conclusion

In Chinese patients with type 2 diabetes inadequately controlled on metformin, the glucose‐lowering effect of cofrogliptin (Q2W) was non‐inferior to linagliptin (daily), with a similar safety profile maintained over 52 weeks of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationGlycated HemoglobinHypoglycemic AgentsLinagliptinMetforminAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseChinaDouble-Blind MethodDrug Administration ScheduleHypoglycemiaTreatment Outcome

Stichwörter der Autor:innen

antidiabetic drugclinical trialdipeptidyl peptidase‐4 inhibitorglycaemic controllinagliptintype 2 diabetes

Substanzen

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsLinagliptinMetformin

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
  • Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Endocrinology, Cangzhou Hospital of Integrated TCM-WM, Cangzhou, China.
  • Department of Endocrinology, Jinan Central Hospital, Jinan, China.
  • Department of Endocrinology and Metabolism, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Endocrinology, Central Hospital of CNPC, Langfang, China.

ORCID-Profile: Qian Ren, Guijun Qin, Linong Ji

Förderung

  • Haisco Pharmaceutical Group Co. Ltd.

Zitieren

APA

Ren, Q., Li, L., Su, X., Hu, X., Qin, G., Han, J., Liu, Y., Wang, J., & Ji, L. (2024). Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15915

Vancouver

Ren Q, Li L, Su X, Hu X, Qin G, Han J, et al. Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15915

BibTeX
@article{Ren2024,
  author = {Ren, Qian and Li, Ling and Su, Xiuhai and Hu, Xiaolin and Qin, Guijun and Han, Jie and Liu, Yu and Wang, Junmin and Ji, Linong},
  title = {Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15915}
}
Kostenlos starten →